RnRMarketResearch.com adds “Supraventricular Tachycardia Global Clinical Trials Review, H2, 2014” report to its research database. This report provides elemental information and data relating to the clinical trials on Supraventricular Tachycardia.

Dallas, TX -- (SBWire) -- 10/07/2014 --Clinical trial report, “Supraventricular Tachycardia Global Clinical Trials Review, H2, 2014? provides data on the Supraventricular Tachycardia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Supraventricular Tachycardia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Supraventricular Tachycardia.

Supraventricular tachycardia (SVT) presents as a rapid heart rhythm originating at or above the atrioventricular node. It can be contrasted with the potentially more dangerous ventricular tachycardias—rapid rhythms that originate within the ventricular tissue. Although "SVT" can be due to any supraventricular cause, the term usually refers to a specific example, paroxysmal supraventricular tachycardia (PSVT), two common types being atrioventricular reciprocating tachycardia and AV nodal reentrant tachycardia. In the older population atrial fibrillation becomes a common type of supraventricular arrhythmias—though it is typically considered separately.

Complete Report Details @ http://www.rnrmarketresearch.com/supraventricular-tachycardia-global-clinical-trials-review-h2-2014-market-report.html .

In general, SVT is caused by one of two mechanisms: re-entry and automaticity. Re-entry (such as AV nodal reentrant tachycardia and atrioventricular reciprocating tachycardia) often presents with an almost immediate increase in heart rate. Someone experiencing this type of PSVT may feel the heart rate accelerate from 60 to 200 beats per minute or more. Typically, when it reverts to normal, this is also sudden.

The main pumping chamber, the ventricle, is protected (to a certain extent) against excessively high rates arising from the supraventricular areas by a 'gating mechanism' at the atrioventricular node, which allows only a proportion of the fast impulses to pass through to the ventricles. In Wolff-Parkinson-White Syndrome, a 'bypass tract' avoids this node and its protection and the fast rate may be directly transmitted to the ventricles. This situation has characteristic findings on ECG.

In 'automaticity' types of SVT (atrial tachycardia, junctional ectopic tachycardia), there is more typically a gradual increase and decrease in the heart rate. These are due to an area in the heart that generates its own electrical signal.

Order a Purchase copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=217365 .

Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Supraventricular Tachycardia 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Clinical Trials by G7 Countries: Proportion of Supraventricular Tachycardia to Cardiovascular Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by E7 Countries: Proportion of Supraventricular Tachycardia to Cardiovascular Clinical Trials 16
Clinical Trials by Phase 17
In Progress Trials by Phase 18
Clinical Trials by Trial Status 19
Clinical Trials by End Point Status 20
Subjects Recruited Over a Period of Time 21
Clinical Trials by Sponsor Type 22
Prominent Sponsors 23
Prominent Drugs 24
Clinical Trial Profiles 25
Clinical Trial Overview of Top Companies 25
Ono Pharmaceutical Co., Ltd. 25
Clinical Trial Overview of Ono Pharmaceutical Co., Ltd. 25
Clinical Trial Overview of Top Institutes / Government 26
Singapore General Hospital 26
Clinical Trial Overview of Singapore General Hospital 26
Tehran University of Medical Sciences 27
Clinical Trial Overview of Tehran University of Medical Sciences 27
Royal Adelaide Hospital 28
Clinical Trial Overview of Royal Adelaide Hospital 28
Schneider Children's Medical Center of Israel 29
Clinical Trial Overview of Schneider Children's Medical Center of Israel 29
University of British Columbia 30
Clinical Trial Overview of University of British Columbia 30
Deutsches Herzzentrum Munchen 31
Clinical Trial Overview of Deutsches Herzzentrum Munchen 31
Catholic University of the Sacred Heart 32
Clinical Trial Overview of Catholic University of the Sacred Heart 32
University of Ottawa Heart Institute 33
Clinical Trial Overview of University of Ottawa Heart Institute 33
University of California, San Francisco 34
Clinical Trial Overview of University of California, San Francisco 34
National Heart, Lung, and Blood Institute 35
Clinical Trial Overview of National Heart, Lung, and Blood Institute 35
Five Key Clinical Profiles 36
Appendix 53
Abbreviations 53
Definitions 53
Research Methodology 54
Secondary Research 54
About GlobalData 55
Contact Us 55
Disclaimer 55
Source 55

List of Tables
Supraventricular Tachycardia Therapeutics, Global, Clinical Trials by Region, 2014* 6
Supraventricular Tachycardia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Supraventricular Tachycardia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Supraventricular Tachycardia Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 9
Supraventricular Tachycardia Therapeutics Clinical Trials, Europe, Top Countries, 2014* 10
Supraventricular Tachycardia Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Supraventricular Tachycardia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 12
Proportion of Supraventricular Tachycardia to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 13
Supraventricular Tachycardia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Supraventricular Tachycardia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Supraventricular Tachycardia to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 16
Supraventricular Tachycardia Therapeutics, Global, Clinical Trials by Phase, 2014* 17
Supraventricular Tachycardia Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 18
Supraventricular Tachycardia Therapeutics, Global, Clinical Trials by Trial Status, 2014* 19
Supraventricular Tachycardia Therapeutics Clinical Trials, Global, by End Point Status, 2014* 20
Supraventricular Tachycardia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 21
Supraventricular Tachycardia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 22
Supraventricular Tachycardia Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 23
Supraventricular Tachycardia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 24
Supraventricular Tachycardia Therapeutics Clinical Trials Market, Global, Clinical Trials by Ono Pharmaceutical Co., Ltd., 2014* 25
Supraventricular Tachycardia Therapeutics Clinical Trials Market, Global, Clinical Trials by Singapore General Hospital, 2014* 26
Supraventricular Tachycardia Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2014* 27
Supraventricular Tachycardia Therapeutics Clinical Trials Market, Global, Clinical Trials by Royal Adelaide Hospital, 2014* 28
Supraventricular Tachycardia Therapeutics Clinical Trials Market, Global, Clinical Trials by Schneider Children's Medical Center of Israel, 2014* 29
Supraventricular Tachycardia Therapeutics Clinical Trials Market, Global, Clinical Trials by University of British Columbia, 2014* 30
Supraventricular Tachycardia Therapeutics Clinical Trials Market, Global, Clinical Trials by Deutsches Herzzentrum Munchen, 2014* 31
Supraventricular Tachycardia Therapeutics Clinical Trials Market, Global, Clinical Trials by Catholic University of the Sacred Heart, 2014* 32
Supraventricular Tachycardia Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Ottawa Heart Institute, 2014* 33
Supraventricular Tachycardia Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014* 34
Supraventricular Tachycardia Therapeutics Clinical Trials Market, Global, Clinical Trials by National Heart, Lung, and Blood Institute, 2014* 35

Browse more reports on Clinical Trial Market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/clinical-trial .